LEADER 03362nam  2200613 a 450 
001 9910141229603321
005 20200520144314.0
010   $a1-283-40104-5
010   $a9786613401045
010   $a1-118-15056-2
010   $a1-118-15057-0
010   $a1-118-15054-6
035   $a(CKB)2670000000131318
035   $a(EBL)818481
035   $a(OCoLC)768082726
035   $a(SSID)ssj0000570331
035   $a(PQKBManifestationID)11369625
035   $a(PQKBTitleCode)TC0000570331
035   $a(PQKBWorkID)10592371
035   $a(PQKB)11617810
035   $a(MiAaPQ)EBC818481
035   $a(Au-PeEL)EBL818481
035   $a(CaPaEBR)ebr10521349
035   $a(CaONFJC)MIL340104
035   $a(PPN)17900297X
035   $a(EXLCZ)992670000000131318
100   $a20110620d2012      uy             0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 00$aAnalysis of aggregates and particles in protein pharmaceuticals$b[electronic resource] /$fedited by Hanns-Christian Mahler, Wim Jiskoot
210   $aHoboken, N.J. $cJohn Wiley & Sons, Inc.$d2012
215   $a1 online resource (474 p.)
300   $aDescription based upon print version of record.
311   $a0-470-49718-1 
320   $aIncludes bibliographical references.
327   $aThe critical need for robust assays for quantitation and characterization of aggregates of therapeutic proteins -- Separation based analytical methods for measuring protein aggregation -- Laser light scattering-based techniques used for the characterization of protein therapeutics -- Online detection methods and emerging techniques for soluble aggregates in protein pharmaceuticals -- Analytical methods to measure sub-visible particulates -- Detection of visible particles in parenteral products -- Characterization of aggregates and particles using emerging techniques -- Ultraviolet absorption spectroscopy -- Fluorescence spectroscopy to characterize protein aggregates and particles -- Infrared spectroscopy to characterize protein aggregates -- Raman microscopy for characterization of particles -- Microscopic methods for particle characterization in protein pharmaceuticals -- Comparison of methods for soluble aggregate detection and size characterization -- Protein purification and its relation to protein aggregation and particles -- Formulation development and its relation to protein aggregation and particles.
330   $aThis book describes how to address the analysis of aggregates and particles in protein pharmaceuticals, provides a comprehensive overview of current methods and integrated approaches used to quantify and characterize aggregates and particles, and discusses regulatory requirements. Analytical methods covered in the book include separation, light scattering, microscopy, and spectroscopy.
606   $aPharmaceutical chemistry
606   $aProtein drugs$xAnalysis
615  0$aPharmaceutical chemistry.
615  0$aProtein drugs$xAnalysis.
676   $a615.1/9
701   $aMahler$b Hanns-Christian$0956764
701   $aJiskoot$b Wim$0956765
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910141229603321
996   $aAnalysis of aggregates and particles in protein pharmaceuticals$92167005
997   $aUNINA